<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121217">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02148471</url>
  </required_header>
  <id_info>
    <org_study_id>03-0505-A</org_study_id>
    <nct_id>NCT02148471</nct_id>
  </id_info>
  <brief_title>Fatty Acids, Genes and Microbiota in Fatty Liver</brief_title>
  <official_title>Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johane Allard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Liver Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first aim of this study is to assess oxidative stress and nutritional status in patients
      with elevated liver enzymes who were found to have either simple steatosis (SS) or
      nonalcoholic steatohepatitis (NASH) or normal histological findings on liver biopsy by
      measuring liver lipid peroxides and tumor necrosis factor (TNF)-α, liver pathology and
      immunohistochemistry, liver function tests, liver and red blood cell membrane fatty
      composition, insulin resistance (IR) parameters, plasma lipid peroxides, plasma antioxidant
      vitamins and antioxidant power, lipid profile, subject demographics, medical history and
      medication use. The second aim is to detect differences in hepatic gene expression
      (messenger RNA, mRNA) and epigenetic regulation (micro RNA, miRNA) between patients with SS
      or NASH and healthy controls, in addition to determine in patients with non-alcoholic fatty
      liver disease (SS+NASH combined) whether there is an association between hepatic n-3 PUFA
      content and gene expression.  The third aim is to determine the intestinal microbiome
      (microbial composition and metagenome) in patients with SS or NASH and healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NASH is associated with obesity, diabetes and hyperlipidemia. Fat accumulation in the liver
      is likely due to variable degrees of disordered fatty-acid metabolism and insulin resistance
      (IR).  Liver steatosis, especially polyunsaturated fatty acids (PUFA) in the liver,
      increases lipid peroxidation and is associated with a reduction in the antioxidant defense
      system. This oxidative stress can lead to increased production of pro-inflammatory cytokines
      (TNF-α, transforming growth factor-beta) contributing to the development of steatohepatitis
      and fibrosis.TNF-α - may further contribute to IR. In addition, changes in fatty acid
      composition within the liver may influence lipid metabolism and inflammation. In particular,
      n-3 PUFA have an effect on the insulin sensitivity, transcription of antioxidant genes,
      inflammatory response and production of reactive oxygen species. Differences might be seen
      on the gene expression level (mRNA) and also in epigenetic regulation (miRNA).

      Microbiota composition might influence energy metabolism, and inflammatory tone and IR
      through increased endotoxemia and therefore could also play a role in the development of
      NAFLD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Hepatic  fatty acid composition in total lipids in liver biopsy</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gas chromatography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic  gene expression</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>mRNA by microarray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal microbiota composition</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Illumina 16S technology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid peroxides in the liver</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Test kit: Bioxytech LPO-586, Oxis International, Portland, OR, which measures free malondialdehyde and 4-hydroxyalkenals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic  liver antioxidant power</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Test kit: TA02, Oxford Biomedical Research, Oxford, MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic  miRNA expression in the liver</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>NanoString</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota - specific organisms and groups</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantitative real-time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiome on a genetic level</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Illumina sequencing technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-chain fatty acids in stool</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gas chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma endotoxin</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Limulus assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hepatic phospoholipid composition</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gas chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell fatty acid and phospholipid composition</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gas chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma fatty acid composition</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gas chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma lipid peroxides</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Test kit</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma antioxidant vitamins</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vitamin C colorimetric, alpha- and gamma-tocopherol and beta-carotene by high-performance liquid chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum antioxidant power</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Test kit</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-alpha  in the liver</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Enzyme linked immunosorbant assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunohistochemistry</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Staining for malondialdehyde, alpha-smooth muscle actin, transforming growth factor beta</description>
  </other_outcome>
  <other_outcome>
    <measure>Free choline in serum</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>liquid chromatography/electrospray ionization-isotope dilution mass spectrometry (LC/ESI-IDMS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bacterial DNA in plasma</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantitative polymerase chain reaction for bacterial 16S rDNA</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting glucose and insulin to calculate HOMA-IR, C-peptide, hemoglobin A1c, all by standard laboratory methods</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma ethanol</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>standard laboratory measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight, height, skinfolds, bioelectrical impedance analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Food intake</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>7-day food records</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>7 day activity logs</description>
  </other_outcome>
  <other_outcome>
    <measure>Factors influencing intestinal microbiota</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Environmental questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver function tests</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Alanine transaminase, aspartate transaminase, alkaline phosphatase, standard laboratory tests</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>Steatosis</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy living liver donors with healthy liver on imaging and/or liver histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simple steatosis</arm_group_label>
    <description>Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonalcoholic steatohepatitis</arm_group_label>
    <description>Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal findings</arm_group_label>
    <description>Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA - samples retained, with potential for extraction of DNA from at least one of the types
      of samples retained (e.g., frozen tissue, whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy living liver donors from the Multiorgan transplant program at the University
        Health Network Patients with nonalcoholic fatty liver disease (SS or NASH on liver biopsy)
        or patients with elevated liver enzymes but no significant findings on liver biopsy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female patients, age &gt;18 y

          -  A liver biopsy with a diagnosis of SS or NASH OR No signs of steatosis, fibrosis or
             any other kind of liver disease on histology   (minimal findings) OR For healthy
             control subjects, those with normal liver enzymes and normal liver imaging on
             ultrasound

          -  alcohol consumption (&lt;20g of ethanol per day);

          -  absence of any other possible cause for liver dysfunction.

        Exclusion criteria:

          -  any other liver disease apart from NAFLD

          -  anticipated need for liver transplantation in one year or complications of liver
             disease;

          -  any reasons contraindicating a liver biopsy (patients) or liver donation (healthy
             donors)

          -  chronic gastrointestinal diseases, previous gastrointestinal surgery modifying the
             anatomy, patients with diabetes requiring insulin.

          -  medications known to precipitate steatohepatitis (corticosteroids, high dose
             estrogens, methotrexate, amiodarone, spironolactone, sulfasalazine, perhexiline
             maleate, diethylamino- ethoxyhexestrol (DH), tamoxifen, diethylstilbestrol, naproxen
             or oxacillin) or regular intake of non-steroidal anti-inflammatory drugs (except for
             low dose aspirin), use of ursodeoxycholic acid or any experimental drug in the 6
             months prior to entry.

          -  regular intake of prebiotics, probiotics, antibiotics, or laxatives; in the 3 months
             prior to study entry

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johane Allard, MD,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johane Allard, MD,FRCPC</last_name>
    <phone>416-340-5159</phone>
    <email>johane.allard@uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianca Arendt, PhD, CCRP</last_name>
    <phone>416-340-4104</phone>
    <email>barendt@uhnresearch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johane Allard, MD,FRCPC</last_name>
      <phone>416-340-5159</phone>
      <email>johane.allard@uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Arendt, PhD, CCRP</last_name>
      <phone>416-340-4104</phone>
      <email>barendt@uhnresaerch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Johane Allard, MD,FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Feb 21;20(7):1712-23. doi: 10.3748/wjg.v20.i7.1712. Review. PubMed</citation>
    <PMID>24587650</PMID>
  </reference>
  <reference>
    <citation>Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DW. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014 Mar;5(3):426-35. doi: 10.1039/c3fo60551e. PubMed</citation>
    <PMID>24496399</PMID>
  </reference>
  <reference>
    <citation>Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2012 Jul;46(6):457-67. doi: 10.1097/MCG.0b013e31824cf51e. Review. PubMed</citation>
    <PMID>22469640</PMID>
  </reference>
  <reference>
    <citation>Mouzaki M, Allard J. Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Ann Gastroenterol. 2012;25(3):207-217. Review. PubMed</citation>
    <PMID>24713803</PMID>
  </reference>
  <results_reference>
    <citation>Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JP. A Cross-Sectional Study Assessing Dietary Intake and Physical Activity in Canadian Patients with Nonalcoholic Fatty Liver Disease vs Healthy Controls. J Acad Nutr Diet. 2014 Mar 14. pii: S2212-2672(14)00099-9. doi: 10.1016/j.jand.2014.01.009. [Epub ahead of print] PubMed</citation>
    <PMID>24631112</PMID>
  </results_reference>
  <results_reference>
    <citation>Arendt BM, Ma DW, Simons B, Noureldin SA, Therapondos G, Guindi M, Sherman M, Allard JP. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40. doi: 10.1139/apnm-2012-0261. Epub 2012 Oct 15. PubMed</citation>
    <PMID>23537027</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013 Feb 11. doi: 10.1002/hep.26319. [Epub ahead of print]</citation>
    <PMID>23401313</PMID>
  </results_reference>
  <results_reference>
    <citation>Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008 Feb;48(2):300-7. Epub 2007 Nov 20.</citation>
    <PMID>18086506</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Johane Allard</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Steatosis</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
